Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
One Percent Rule Checklist For Safer Forex Trading Risk 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
South Korea will invest 520 billion won in biotechnology next year to boost its development of treatment and vaccines for COVID-19.
The Ministry of Science and ICT said the figure represents a 24.9 percent hike from 2020.
Of that amount, 31.7 billion won will go to COVID-19 treatment and vaccine development and 10.2 billion won for technology to respond to new infectious diseases.
Some of it will also go to research into new core biotech industries, such as 71 billion won to develop a new medicine, 61.8 billion won in medical devices, and 31.1 billion won in regenerative medicine to strengthen research in stem cell technology and others.
The medical devices to be developed targets the elderly and the disabled.
The ministry said it also plans to invest 51.3 billion won to acquire next-generation biotech, such as single-cell analysis.
Last month, 36 South Korean biotech and pharmaceutical companies announced that they invest a combined 10 trillion won by 2023 to hone their competitiveness and technological capabilities.
The firms include Samsung Biologics Co. and Celltrion Inc., will
The government intends to spend a total of 2.2 trillion won on developing new medicine until 2030.
